NLRP1 and COVID-19: NLRP1 knockdown blocked the activation of Casp1 and Casp6 in intraneuronal inflammation.[10] The inhibition of NLRP1/ASC inflammasome attenuated inflammatory response in fructose-induced retinal ganglion cells, suggesting NLRP1 inflammasome might be a potential biomarker against diabetic retinopathy.[11] However, up to now, limited researches focused on the role of NLRP1 and inflammatory cytokines in COVID-19 patients on transpyloric enteral nutrition (TEN).